

Supreme Innovator - Otago's Pacific Edge



Congratulations to Pacific Edge! It's been a stellar twelve months of remarkable achievements for the Dunedin-based company, and there is plenty to celebrate.

In 2013 and 2014 Pacific Edge:

- Launched Cxbladder, a potentially life-saving bladder cancer test that, unlike other tests on the market, is non-invasive, fast, accessible, inexpensive and extremely accurate.
- Won the NZ Innovation Council's **Supreme Innovator Award**.
- Were named **Business of the Year** by the Otago Daily Times.
- Opened a custom-built laboratory in Pennsylvania, USA, which has capacity to process 4,000 Cxbladder tests per week.
- Achieved CLIA (Clinical Laboratory Improvements Amendments) accreditation for both its US and Dunedin based laboratories.

- [Achieved NZ DHB support](#) to fast-track the introduction of Cxbladder tests to the four main DHB boards.
- Signed agreements with three National Provider Networks in USA and started commercial sales in the giant American healthcare market.
- Skyrocketed up the stock market and will soon join the NZX50.

Pacific Edge formed in 2001 to commercialise world-leading cancer genetics research from the University. Cxbladder is a new, non-invasive, urine based bladder cancer detection test that measures the expression of five genes that create a unique molecular signature for bladder cancer, alerting doctors to possible tumours or helping to rule out the presence of cancer in patients. More accurate than many other urine-based cancer detection tests, Cxbladder can give patients and doctors added confidence in their diagnoses quickly and cost effectively.

Pacific Edge aims to launch two more unique products soon ...

[Read an in depth article about CxBladder and Pacific Edge](#)

[Check out the Pacific Edge website](#)

[Listen to the National Radio interview with David Darling: "Getting a breakthrough cancer diagnosis test to market"](#)